Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Alba Iulia – page 5

99 clinical trials in Alba Iulia, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Alba Iulia at a glance
99
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

99 trials in Alba Iulia

Open in trial search

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Study of Zolbetuximab and CAPOX for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Study Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Formycon AG

Gastric cancer+2

Not recruiting

Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Arcus Biosciences Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Alba Iulia

What the registry says about research in the country

01 Diabetes & Cardiovascular Research

Innovative research focusing on Type 2 Diabetes Mellitus management, specifically evaluating new therapeutic approaches for cardiovascular risk reduction.

  • Comparative effectiveness studies
  • Cardiovascular outcomes
  • Standard of care optimization

Groundbreaking trials examining the impact of novel treatments on major cardiovascular events in diabetic patients.

02 Metabolic Disorders

Clinical investigations targeting severe hypertriglyceridemia, exploring innovative therapeutic approaches to manage elevated triglyceride levels.

  • Lipid metabolism
  • Triglyceride reduction
  • Metabolic health

Advanced research aimed at developing effective treatments for complex metabolic conditions.

03 Oncology Research

Comprehensive studies in clear cell renal cell carcinoma and various cancer types, investigating combination therapies including immune and targeted treatments.

  • Immunotherapy combinations
  • Targeted therapeutics
  • Cancer progression markers

Evaluating innovative treatment approaches for advanced cancer care and survival outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.